Aroa Biosurgery Limited
Developer, manufacturer and distributor of extracellular-matrix (ECM)–based bioscaffolds and related surgical devices for soft-tissue repair and wound management. Headquartered in Auckland, New Zealand (founded 2008). Maintains regulated quality systems and international regulatory clearances for multiple wound- and reconstruction-focused medical devices and biomaterials.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Myriad Morcells
Morselized ECM product available in particulate formats for wound and reconstructive applications.
Myriad Morcells Fine
Fine powder/particulate ECM format intended for wound management applications and use in combination with other scaffolds.
Myriad Meshed
Fenestrated/meshed ECM bioscaffold configuration for wound management.
Myriad Matrix
Surgical soft tissue bioscaffold indicated for complex wounds, reconstruction and soft tissue reinforcement.
Symphony
Combination cellular and tissue product comprising an ECM scaffold integrated with hyaluronic acid intended for wound management.
Endoform (restorative bioscaffolds)
ECM restorative bioscaffolds, including natural and antimicrobial variants, for management of acute and chronic wounds.
Myriad Morcells
Morselized ECM product available in particulate formats for wound and reconstructive applications.
Myriad Morcells Fine
Fine powder/particulate ECM format intended for wound management applications and use in combination with other scaffolds.
Myriad Meshed
Fenestrated/meshed ECM bioscaffold configuration for wound management.
Myriad Matrix
Surgical soft tissue bioscaffold indicated for complex wounds, reconstruction and soft tissue reinforcement.
Symphony
Combination cellular and tissue product comprising an ECM scaffold integrated with hyaluronic acid intended for wound management.
Endoform (restorative bioscaffolds)
ECM restorative bioscaffolds, including natural and antimicrobial variants, for management of acute and chronic wounds.
Services
Provision of reimbursement resources, payer coding information and a support contact for clinicians and providers.
Virtual product overview sessions and educational support for clinicians evaluating wound-care and reconstructive products.
Provision of reimbursement resources, payer coding information and a support contact for clinicians and providers.
Virtual product overview sessions and educational support for clinicians evaluating wound-care and reconstructive products.
Expertise Areas
- Wound care and soft-tissue repair
- ECM biomaterials development
- Composite biomaterial formulation (ECM + biologic excipients)
- Surgical device development and postoperative management systems
Key Technologies
- Extracellular matrix (ECM) bioscaffolds
- Particulate and fine powder ECM formats
- Meshed/fenestrated ECM sheet configurations
- Reinforced composite scaffolds combining ECM and structural materials
News & Updates
Audited full year financial results for FY24, including revenue (NZ$69.1M total, NZ$68.0M product revenue), margin and FY25 guidance.
Exclusive agreement to co-promote Endoform in the United States to expand access in post-acute settings; Aroa retains manufacturing and ownership.
Press release summarizing results of a prospective, multicenter randomized controlled trial reporting higher complete wound-closure rates and reduced mean healing time when an ECM–hyaluronic acid composite was added to standard of care for diabetic foot ulcers.
Certified to ISO 13485:2016 and expanded quality management system scope under MDSAP covering the United States, Canada, Australia and Brazil.
Publication of multicentre RCT data demonstrating improved healing outcomes for diabetic foot ulcers when an ECM–HMWHA composite was added to standard of care.
Audited full year financial results for FY24, including revenue (NZ$69.1M total, NZ$68.0M product revenue), margin and FY25 guidance.
Exclusive agreement to co-promote Endoform in the United States to expand access in post-acute settings; Aroa retains manufacturing and ownership.
Press release summarizing results of a prospective, multicenter randomized controlled trial reporting higher complete wound-closure rates and reduced mean healing time when an ECM–hyaluronic acid composite was added to standard of care for diabetic foot ulcers.
Certified to ISO 13485:2016 and expanded quality management system scope under MDSAP covering the United States, Canada, Australia and Brazil.
Publication of multicentre RCT data demonstrating improved healing outcomes for diabetic foot ulcers when an ECM–HMWHA composite was added to standard of care.